Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.164
https://www.valueinhealthjournal.com/article/S1098-3015(13)02069-X/fulltext
Title : Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02069-X&doi=10.1016/j.jval.2013.08.164
First page : A350
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 151
Categories :
Tags :
Regions :
ViH Article Tags :